AbbVie Inc. vs Samsung Electronics Co., Ltd.: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Samsung Electronics Co., Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Samsung Electronics Co., Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Samsung Electronics Co., Ltd. is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $233.3B for Samsung Electronics Co., Ltd., while their respective market capitalizations stand at $451.5B and $1.20T. AbbVie Inc. is headquartered in United States and Samsung Electronics Co., Ltd. operates from South Korea, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

Samsung Electronics Co., Ltd.: Samsung is unusually broad for a technology company. It is a national industrial champion, a memory supplier, a smartphone competitor, a display maker, an appliance company, and an automotive electronics owner through Harman. That breadth is both the moat and the management challenge.

AbbVie Inc. and Samsung Electronics Co., Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Samsung Electronics Co., Ltd..

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

Samsung Electronics Co., Ltd. business model: Samsung earns revenue from memory semiconductors including DRAM, NAND, and HBM; system LSI and foundry; Galaxy smartphones and tablets; display panels; TVs and appliances; network equipment; and Harman automotive and audio products. Memory cycles often drive profits even when smartphones drive brand visibility.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Samsung Electronics Co., Ltd..

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

Samsung Electronics Co., Ltd. competitive advantage: Samsung advantage is vertical integration across memory, displays, processors, devices, appliances, and manufacturing. It can supply components to competitors while also using those components in its own Galaxy devices and consumer electronics ecosystem.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Samsung Electronics Co., Ltd. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

Samsung Electronics Co., Ltd. growth strategy: Samsung growth strategy is built around AI memory, HBM3E and HBM4, advanced packaging, 3nm and next-generation foundry nodes, Galaxy AI devices, premium OLED and TV products, connected appliances, networks, and Harman automotive electronics.

A closer look at the financial trajectory of AbbVie Inc. and Samsung Electronics Co., Ltd. rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

Samsung Electronics Co., Ltd.: Samsung reported KRW 333.6 trillion in 2025 annual revenue and KRW 43.6 trillion in operating profit. Fourth-quarter revenue reached KRW 93.8 trillion, the highest quarterly consolidated revenue in company history, and fourth-quarter operating profit was KRW 20.1 trillion.